Vacunek Overview

  • Year Founded
  • 2006

Year Founded

  • Status
  • Out of Business

  • Latest Deal Type
  • Out of Business

Vacunek General Information


Developer of biotechnology products intended to focus on the application of new biotechnological tools for animal health. The company's products are used as a development of biological immunity against animal mycobacteriosis in livestock and wild species, enabling farmers to detect and cure various bacterial animal diseases.

Contact Information

Ownership Status
Out of Business
Financing Status
Formerly VC-backed
Primary Industry
Other Industries
Drug Discovery
Corporate Office
  • Teknologi Parkea, Astondo Bidea
  • Edificio 612, Vizcaya
  • 48160 Derio
  • Spain
+34 946 00 00 00

Want detailed data on 3M+ companies?

What you see here scratches the surface

Request a free trial

Want to dig into this profile?

We’ll help you find what you need

Learn more

Vacunek Valuation & Funding

Deal Type Date Amount Raised to Date Post-Val Status Stage
2. Out of Business 01-Nov-2019 00000 Completed Out of Business
1. Seed Round 01-Jan-2007 00000 00000 00.000 Completed Startup
To view Vacunek’s complete valuation and funding history, request access »

Vacunek FAQs

  • When was Vacunek founded?

    Vacunek was founded in 2006.

  • Where is Vacunek headquartered?

    Vacunek is headquartered in Derio, Spain.

  • What industry is Vacunek in?

    Vacunek’s primary industry is Biotechnology.

  • Is Vacunek a private or public company?

    Vacunek is a Private company.

  • What is Vacunek’s current revenue?

    The current revenue for Vacunek is 00000.

  • How much funding has Vacunek raised over time?

    Vacunek has raised $277K.

Data Transparency

  • Meet our data hygiene team

    Discover how our experts ensure you’re getting the most accurate financial data in the industry.

    Read blog »
  • How PitchBook sources data

    Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.

    Discover our process »